OA11612A - Method of delivering genes to antigen presenting cells of the skin. - Google Patents
Method of delivering genes to antigen presenting cells of the skin. Download PDFInfo
- Publication number
- OA11612A OA11612A OA1200000074A OA1200000074A OA11612A OA 11612 A OA11612 A OA 11612A OA 1200000074 A OA1200000074 A OA 1200000074A OA 1200000074 A OA1200000074 A OA 1200000074A OA 11612 A OA11612 A OA 11612A
- Authority
- OA
- OAPI
- Prior art keywords
- cells
- gene delivery
- complex
- delivery complex
- dna
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 103
- 238000000034 method Methods 0.000 title claims abstract description 50
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims abstract description 139
- 238000001476 gene delivery Methods 0.000 claims abstract description 75
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 59
- 230000003053 immunization Effects 0.000 claims abstract description 25
- 238000002649 immunization Methods 0.000 claims abstract description 23
- 230000002068 genetic effect Effects 0.000 claims abstract description 16
- 210000004443 dendritic cell Anatomy 0.000 claims description 80
- 229920002873 Polyethylenimine Polymers 0.000 claims description 47
- 241000700605 Viruses Species 0.000 claims description 39
- 210000001821 langerhans cell Anatomy 0.000 claims description 28
- 108010031099 Mannose Receptor Proteins 0.000 claims description 26
- 102000005962 receptors Human genes 0.000 claims description 26
- 108020003175 receptors Proteins 0.000 claims description 26
- 230000003612 virological effect Effects 0.000 claims description 26
- 210000003491 skin Anatomy 0.000 claims description 22
- 235000000346 sugar Nutrition 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 19
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000010837 receptor-mediated endocytosis Effects 0.000 claims description 10
- 230000009385 viral infection Effects 0.000 claims description 8
- 239000000890 drug combination Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 150000008163 sugars Chemical class 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 102100034343 Integrase Human genes 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 208000037357 HIV infectious disease Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 4
- 108010061833 Integrases Proteins 0.000 claims description 2
- 241000014654 Adna Species 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020004705 Codon Proteins 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000002463 transducing effect Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 11
- 238000010361 transduction Methods 0.000 abstract description 8
- 230000026683 transduction Effects 0.000 abstract description 8
- 108700005077 Viral Genes Proteins 0.000 abstract description 7
- 230000007246 mechanism Effects 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 64
- 108091007433 antigens Proteins 0.000 description 49
- 102000036639 antigens Human genes 0.000 description 49
- 239000000427 antigen Substances 0.000 description 48
- 239000002245 particle Substances 0.000 description 38
- 238000001727 in vivo Methods 0.000 description 26
- 238000000338 in vitro Methods 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 20
- 210000001165 lymph node Anatomy 0.000 description 20
- 239000013612 plasmid Substances 0.000 description 18
- 238000012546 transfer Methods 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 210000001163 endosome Anatomy 0.000 description 16
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 14
- 210000000987 immune system Anatomy 0.000 description 14
- 230000001404 mediated effect Effects 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 14
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 13
- 230000002950 deficient Effects 0.000 description 13
- 229940027941 immunoglobulin g Drugs 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 230000024932 T cell mediated immunity Effects 0.000 description 12
- 239000005090 green fluorescent protein Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000028996 humoral immune response Effects 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 108010087819 Fc receptors Proteins 0.000 description 9
- 102000009109 Fc receptors Human genes 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 239000002502 liposome Substances 0.000 description 8
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 230000012202 endocytosis Effects 0.000 description 7
- 230000008782 phagocytosis Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 101710149951 Protein Tat Proteins 0.000 description 6
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102000004338 Transferrin Human genes 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 210000005210 lymphoid organ Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000012581 transferrin Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 239000000277 virosome Substances 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 3
- 108090000901 Transferrin Proteins 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 210000000680 phagosome Anatomy 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282561 Macaca nemestrina Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 102000016979 Other receptors Human genes 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 108010033576 Transferrin Receptors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 108010078428 env Gene Products Proteins 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 230000014207 opsonization Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- -1 phenyl mannose Chemical compound 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 208000037816 tissue injury Diseases 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- 101150098072 20 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700010908 HIV-1 proteins Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000007238 Transferrin Receptors Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- GLNADSQYFUSGOU-UHFFFAOYSA-J chembl1640 Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(N=NC3=CC=C(C=C3C)C=3C=C(C(=CC=3)N=NC=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-UHFFFAOYSA-J 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000001911 interdigitating cell Anatomy 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5893397P | 1997-09-15 | 1997-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11612A true OA11612A (en) | 2004-08-13 |
Family
ID=22019811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200000074A OA11612A (en) | 1997-09-15 | 1998-09-15 | Method of delivering genes to antigen presenting cells of the skin. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US6420176B1 (ko) |
| EP (1) | EP1024836B1 (ko) |
| JP (1) | JP2001516729A (ko) |
| KR (1) | KR100615117B1 (ko) |
| CN (1) | CN100391542C (ko) |
| AP (1) | AP1427A (ko) |
| AT (1) | ATE347911T1 (ko) |
| AU (1) | AU754425B2 (ko) |
| BR (1) | BR9813202B1 (ko) |
| CA (1) | CA2302316A1 (ko) |
| DE (1) | DE69836643T2 (ko) |
| EA (1) | EA003832B1 (ko) |
| ES (1) | ES2279580T3 (ko) |
| IL (2) | IL134842A0 (ko) |
| NO (1) | NO327491B1 (ko) |
| NZ (1) | NZ503334A (ko) |
| OA (1) | OA11612A (ko) |
| WO (1) | WO1999013915A1 (ko) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US20020022034A1 (en) * | 1997-09-15 | 2002-02-21 | Julianna Lisziewicz | Therapeutic DNA vaccination |
| EP1024836B1 (en) * | 1997-09-15 | 2006-12-13 | Genetic Immunity, LLC | Compositions for delivering genes to antigen presenting cells of the skin |
| WO1999041403A1 (en) * | 1998-02-12 | 1999-08-19 | The Regents Of The University Of California | Compositions for receptor/liposome mediated transfection and methods of using same |
| US7091192B1 (en) * | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US7375096B1 (en) * | 1998-12-04 | 2008-05-20 | California Institute Of Technology | Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network |
| US20020006412A1 (en) * | 2000-04-28 | 2002-01-17 | Roberts Bruce L. | Preparation and use of particulates composed of adenovirus particles |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| CN102516417B (zh) | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | 用于传递治疗剂的以环糊精为基础的聚合物 |
| RU2005114007A (ru) * | 2002-10-09 | 2005-10-10 | Инсерт Терапьютикс, Инк. (Us) | Материалы на основе циклодекстринов, их композиции и применение |
| WO2004065575A2 (en) | 2003-01-15 | 2004-08-05 | Research Institute For Genetic And Human Therapy (Right) | Dna compositon and uses thereof |
| CA2549840C (en) * | 2003-12-09 | 2012-03-20 | Engeneic Molecular Delivery Pty Ltd. | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
| US7541185B2 (en) | 2003-12-23 | 2009-06-02 | Cythera, Inc. | Methods for identifying factors for differentiating definitive endoderm |
| US7625753B2 (en) | 2003-12-23 | 2009-12-01 | Cythera, Inc. | Expansion of definitive endoderm cells |
| US7985585B2 (en) | 2004-07-09 | 2011-07-26 | Viacyte, Inc. | Preprimitive streak and mesendoderm cells |
| US20050266554A1 (en) | 2004-04-27 | 2005-12-01 | D Amour Kevin A | PDX1 expressing endoderm |
| CN103898045B (zh) | 2003-12-23 | 2019-02-01 | 维亚希特公司 | 定形内胚层 |
| US8586357B2 (en) | 2003-12-23 | 2013-11-19 | Viacyte, Inc. | Markers of definitive endoderm |
| US8647873B2 (en) | 2004-04-27 | 2014-02-11 | Viacyte, Inc. | PDX1 expressing endoderm |
| EP2377922B1 (en) | 2004-04-27 | 2020-04-08 | Viacyte, Inc. | PDX1 expressing endoderm |
| US7217428B2 (en) * | 2004-05-28 | 2007-05-15 | Technology Innovations Llc | Drug delivery apparatus utilizing cantilever |
| US7740861B2 (en) * | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| CN102925406B (zh) | 2004-07-09 | 2019-11-22 | 维亚希特公司 | 鉴定用于分化定型内胚层的因子的方法 |
| WO2006020919A2 (en) | 2004-08-13 | 2006-02-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods for self-renewal and differentiation in human embryonic stem cells |
| CN101052383B (zh) * | 2004-09-17 | 2013-01-30 | 马萨诸塞大学 | 用于溶酶体酶缺乏症的组合物和其用途 |
| KR20060073172A (ko) | 2004-12-24 | 2006-06-28 | 재단법인서울대학교산학협력재단 | 생체 고분자/유전자 복합체 |
| BRPI0501037B8 (pt) * | 2005-03-18 | 2021-07-27 | Fund De Amparo A Pesquisa Do Estado De Sao Paulo | uso de crotamina e composição |
| ATE526991T1 (de) * | 2005-10-24 | 2011-10-15 | Univ Massachusetts | Zusammensetzungen und ihre verwendungen für die gentherapeutische behandlung von knochenerkrankungen |
| EP1957636B1 (en) | 2005-10-27 | 2018-07-04 | Viacyte, Inc. | Pdx1-expressing dorsal and ventral foregut endoderm |
| US11254916B2 (en) | 2006-03-02 | 2022-02-22 | Viacyte, Inc. | Methods of making and using PDX1-positive pancreatic endoderm cells |
| EP2650359B1 (en) | 2006-03-02 | 2022-05-04 | Viacyte, Inc. | Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production |
| US7695965B2 (en) | 2006-03-02 | 2010-04-13 | Cythera, Inc. | Methods of producing pancreatic hormones |
| WO2007127454A2 (en) | 2006-04-28 | 2007-11-08 | Cythera, Inc. | Hepatocyte lineage cells |
| US20080176958A1 (en) | 2007-01-24 | 2008-07-24 | Insert Therapeutics, Inc. | Cyclodextrin-based polymers for therapeutics delivery |
| US7695963B2 (en) | 2007-09-24 | 2010-04-13 | Cythera, Inc. | Methods for increasing definitive endoderm production |
| JP2011517279A (ja) * | 2007-10-29 | 2011-06-02 | ユニバーシティ オブ マサチューセッツ | 核酸（ｓｉＲＮＡ）送達用の酵母細胞壁粒子（ＹＣＷＰ）多層状ナノ粒子 |
| BRPI0819262A2 (pt) | 2007-11-08 | 2017-05-02 | Neogenix Oncology Inc | anticorpos monoclonais recombinantes e antìgenos correspondentes para cânceres de cólon e pancreático |
| WO2010008582A2 (en) * | 2008-07-18 | 2010-01-21 | Rxi Pharmaceuticals Corporation | Phagocytic cell drug delivery system |
| EP3336188B1 (en) | 2008-09-22 | 2020-05-06 | Phio Pharmaceuticals Corp. | Reduced size self-delivering rnai compounds |
| EP4176888A1 (en) | 2008-11-14 | 2023-05-10 | ViaCyte, Inc. | Encapsulation of pancreatic cells derived from human pluripotent stem cells |
| US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| HU0900117D0 (en) | 2009-02-26 | 2009-04-28 | Genetic Immunity Kutatasi | Topical or transdermal delivery kit |
| EP2623117A1 (en) * | 2009-04-30 | 2013-08-07 | Genetic Immunity Kft. | Immunogenic nanomedicine composition and preparation and uses thereof |
| CN104208716A (zh) * | 2009-11-23 | 2014-12-17 | 天蓝制药公司 | 用于传递治疗剂的基于环糊精的聚合物 |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| IL265674B2 (en) | 2010-03-24 | 2024-05-01 | Phio Pharm Corp | Rana disorder in cutaneous and fibrotic symptoms |
| EP3372248B1 (en) | 2010-06-22 | 2020-03-11 | Onxeo | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| AU2015202211B2 (en) * | 2010-06-22 | 2016-09-01 | Centre National De La Recherche Scientifique | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
| CN102146416B (zh) * | 2010-12-30 | 2013-03-13 | 江苏大学 | 阳离子化杏鲍菇多糖纳米粒基因传递系统及其制法 |
| EP2527440A1 (en) * | 2011-05-27 | 2012-11-28 | Institut Curie | Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia |
| WO2014055493A1 (en) | 2012-10-02 | 2014-04-10 | Cerulean Pharma Inc. | Methods and systems for polymer precipitation and generation of particles |
| CN105722530B (zh) | 2013-08-16 | 2020-06-02 | 罗切斯特大学 | 用于紧密连接屏障调节的设计肽 |
| CN107073294A (zh) | 2014-09-05 | 2017-08-18 | 阿克赛医药公司 | 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法 |
| CA2993270C (en) | 2015-07-23 | 2019-07-16 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
| CN105396140B (zh) * | 2015-12-02 | 2019-07-02 | 浙江医药高等专科学校 | 抗肿瘤免疫治疗纳米给药系统及其构建方法 |
| WO2020247347A1 (en) | 2019-06-05 | 2020-12-10 | University Of Rochester | New designed inhibitors of tight junction formation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5620896A (en) * | 1992-03-23 | 1997-04-15 | University Of Massachusetts Medical Center | DNA vaccines against rotavirus infections |
| AU2242799A (en) * | 1994-02-22 | 1999-05-27 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| CA2194488A1 (en) * | 1994-08-05 | 1996-02-15 | Tod Paul Holler | Method of using transdominant negative retroviral integrase in the treatment of retroviral infection |
| AU707734B2 (en) * | 1995-06-07 | 1999-07-15 | Regents Of The University Of California, The | Stabilization of polynucleotide complexes |
| DE19605279A1 (de) * | 1996-02-13 | 1997-08-14 | Hoechst Ag | Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung |
| ATE429505T1 (de) * | 1996-02-21 | 2009-05-15 | Genetic Immunity Kft | Verfahren und zusammensetzungen zur genetisch schützenden und therapeutischen immunisierung |
| FR2747046B1 (fr) * | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
| EP1024836B1 (en) * | 1997-09-15 | 2006-12-13 | Genetic Immunity, LLC | Compositions for delivering genes to antigen presenting cells of the skin |
-
1998
- 1998-09-15 EP EP98947128A patent/EP1024836B1/en not_active Expired - Lifetime
- 1998-09-15 DE DE69836643T patent/DE69836643T2/de not_active Expired - Lifetime
- 1998-09-15 IL IL13484298A patent/IL134842A0/xx active IP Right Grant
- 1998-09-15 EA EA200000325A patent/EA003832B1/ru not_active IP Right Cessation
- 1998-09-15 NZ NZ503334A patent/NZ503334A/en unknown
- 1998-09-15 OA OA1200000074A patent/OA11612A/en unknown
- 1998-09-15 AT AT98947128T patent/ATE347911T1/de not_active IP Right Cessation
- 1998-09-15 CA CA002302316A patent/CA2302316A1/en not_active Abandoned
- 1998-09-15 BR BRPI9813202-4A patent/BR9813202B1/pt not_active IP Right Cessation
- 1998-09-15 CN CNB988111675A patent/CN100391542C/zh not_active Expired - Fee Related
- 1998-09-15 JP JP2000511529A patent/JP2001516729A/ja active Pending
- 1998-09-15 ES ES98947128T patent/ES2279580T3/es not_active Expired - Lifetime
- 1998-09-15 AU AU93980/98A patent/AU754425B2/en not_active Ceased
- 1998-09-15 US US09/153,198 patent/US6420176B1/en not_active Expired - Fee Related
- 1998-09-15 WO PCT/US1998/019498 patent/WO1999013915A1/en active IP Right Grant
- 1998-09-15 AP APAP/P/2000/001762A patent/AP1427A/en active
- 1998-09-15 KR KR1020007002661A patent/KR100615117B1/ko not_active IP Right Cessation
-
2000
- 2000-03-01 IL IL134842A patent/IL134842A/en not_active IP Right Cessation
- 2000-03-09 NO NO20001244A patent/NO327491B1/no not_active IP Right Cessation
-
2002
- 2002-02-21 US US10/081,922 patent/US7910562B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2302316A1 (en) | 1999-03-25 |
| EA200000325A1 (ru) | 2000-10-30 |
| IL134842A0 (en) | 2001-05-20 |
| ATE347911T1 (de) | 2007-01-15 |
| EP1024836B1 (en) | 2006-12-13 |
| AU754425B2 (en) | 2002-11-14 |
| EP1024836A4 (en) | 2003-07-02 |
| NZ503334A (en) | 2002-05-31 |
| KR100615117B1 (ko) | 2006-08-22 |
| CN1278739A (zh) | 2001-01-03 |
| CN100391542C (zh) | 2008-06-04 |
| ES2279580T3 (es) | 2007-08-16 |
| DE69836643D1 (de) | 2007-01-25 |
| AU9398098A (en) | 1999-04-05 |
| IL134842A (en) | 2009-02-11 |
| AP2000001762A0 (en) | 2000-03-31 |
| BR9813202B1 (pt) | 2011-11-01 |
| WO1999013915A1 (en) | 1999-03-25 |
| DE69836643T2 (de) | 2007-09-27 |
| BR9813202A (pt) | 2000-08-29 |
| US7910562B2 (en) | 2011-03-22 |
| AP1427A (en) | 2005-06-07 |
| US6420176B1 (en) | 2002-07-16 |
| US20020193333A1 (en) | 2002-12-19 |
| JP2001516729A (ja) | 2001-10-02 |
| NO20001244L (no) | 2000-05-15 |
| KR20010030598A (ko) | 2001-04-16 |
| EA003832B1 (ru) | 2003-10-30 |
| EP1024836A1 (en) | 2000-08-09 |
| NO327491B1 (no) | 2009-07-20 |
| NO20001244D0 (no) | 2000-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU754425B2 (en) | Method of delivering genes to antigen presenting cells of the skin | |
| JP7348063B2 (ja) | ワクチン効力を改善するためのシステム及び方法 | |
| AU666127B2 (en) | Induction of cytotoxic T-lymphocyte responses | |
| WO2006083289A2 (en) | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity | |
| KR20010072983A (ko) | Ｄｎａ 접종 방법 | |
| KR20180063885A (ko) | 전이 감소를 위한 방법 및 조성물 | |
| D’haese et al. | Off the beaten path: Novel mRNA-nanoformulations for therapeutic vaccination against HIV | |
| Peeler et al. | Lytic polyplex vaccines enhance antigen‐specific cytotoxic T cell response through induction of local cell death | |
| US6562800B1 (en) | Use of immunopotentiating sequences for inducing immune response | |
| WO1997032987A1 (en) | Methods and nucleic immunogenic compositions encoding antigens and co-stimulatory molecules for immunization | |
| EP0422164A1 (en) | LARGE SIZE MULTIVALENT IMMUNOGEN. | |
| US20020022034A1 (en) | Therapeutic DNA vaccination | |
| MXPA00002522A (en) | Method of delivering genes to antigen presenting cells of the skin | |
| Choudary et al. | Enhanced immune response of DNA vaccine (VP1-pCDNA) adsorbed on cationic PLG for foot and mouth disease in guinea pigs | |
| US20220162644A1 (en) | Delivery vectors and particles for expressing chimeric receptors and methods of using the same | |
| US20240207387A1 (en) | A vaccine adjuvant for infectious diseases | |
| Votaw | Polysequence Nanomaterials for Immunomodulation | |
| Sun | Protein Engineering Approaches towards Respiratory Disease Prevention and Therapeutics: From Lung Cancer to COVID-19 | |
| Kang et al. | Genetic immunisation and treatment of disease | |
| De Beuckelaer | mRNA-based vaccines to elicit CD8⁺ T cell immunity | |
| Gould-Fogerite et al. | Liposomes: use as gene transfer vehicles and vaccines. |